Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Genprex Inc (GNPX)

Genprex Inc (GNPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Genprex (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy Investor Brand Network - Wed Apr 3, 8:49AM CDT

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering Investor Brand Network - Tue Mar 26, 9:21AM CDT

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering,...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering Investor Brand Network - Wed Mar 20, 9:37AM CDT

Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company today announced its entry into definitive...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to IP Portfolio Investor Brand Network - Thu Mar 14, 9:21AM CDT

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has received a Notice of Patent Grant from the Korean...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Preclinical Data to be Presented at AACR Annual Meeting Investor Brand Network - Thu Mar 7, 9:36AM CST

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be presenting its research at next month’s 2024...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs Investor Brand Network - Thu Feb 8, 9:15AM CST

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is expanding its nonclinical programs into new indications....

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Announces Participation at BIO CEO & Investor Conference Investor Brand Network - Wed Feb 7, 9:54AM CST

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be represented at the upcoming BIO CEO & Investor...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Phase 2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient Investor Brand Network - Tue Feb 6, 9:28AM CST

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has enrolled and dosed the first patient in the phase...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer Investor Brand Network - Wed Nov 22, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”)...

GNPX : 0.9100 (+1.11%)
Genprex (NASDAQ: GNPX) to Present at BIO-Europe 2023 Investor Brand Network - Thu Nov 2, 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general...

GNPX : 0.9100 (+1.11%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot